Exchange Bulletin
Aralez Pharmaceuticals Inc. (ARZ) To Trade On Toronto Stock Exchange
Aralez Pharmaceuticals Inc. (the “Company”) – An application has been granted for the original listing in the Industrial category of approximately 93,018,908 common shares (the “Shares”) of the Company, of which approximately 63,960,319 will be issued and outstanding and approximately 29,058,589 will be reserved for issuance pursuant to a series of transactions (collectively, the “Transaction”), including a merger and a plan of arrangement involving, among others, Tribute Pharmaceuticals Canada Inc. (TSXV Symbol: TRX) (“Tribute”) and POZEN Inc. (NASDAQ Symbol: POZN) (“Pozen”), which are described in the management information circular of Tribute dated January 5, 2016 (the “Circular”). Listing of the Shares will become effective at 5:01 p.m. on Monday, February 8, 2016. The Shares will be posted for trading on Toronto Stock Exchange at the opening of business on Tuesday, February 9, 2016.
Additional information on the Shares may be found in the Circular, which is available at www.SEDAR.com. Capitalized terms not otherwise defined herein are as defined in the Circular.
The Company is subject to the reporting requirements of Section 501 of the TSX Company Manual.
| Stock Symbol: "ARZ" | CUSIP: 03852X 10 0 | Trading Currency: CDN$ |
| Temporary Market Maker: | Altacorp Capital Inc. |
| Other Markets: | The Shares will be listed on NASDAQ Global Market and posted for trading under the symbol “ARLZ” upon completion of the Transaction. The common shares of Tribute have been listed on TSX Venture Exchange since May 27, 2014 and will be delisted at the close of business on Monday, February 8, 2016. |
| Head Office Address: | 2800 Park Place, 666 Burrard Street Vancouver, British Columbia V6C 2Z7 |
| Website Address: | www.aralez.com |
| Head Office Telephone Number: | (919) 913-1030 |
| Fax Number: | (919)-913-1039 |
| Investor Relations: | Nichol Ochsner Tel.: (919) 913-1030 Email: nochsner@aralez.com |
| Incorporation: | The Company was formed on December 2, 2015 under the Business Corporations Act (British Columbia). |
| Fiscal Year End: | December 31 |
| Sponsorship: | Waived |
| Chief Financial Officer: | Scott J. Charles |
| Corporate Secretary: | Eric L. Trachtenberg |
| Nature of Business: | The Company is a holding company which, upon closing of the Transaction, will wholly own, among other companies, Tribute, a specialty pharmaceutical company focused on the acquisition, licensing, development and promotion of healthcare products for the Canadian and American markets, and Pozen, a U.S.-based, specialty pharmaceutical company focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. |
| Transfer Agent & Registrar: | Computershare Investor Services Inc. at its principal office in Vancouver, British Columbia. |
| Dividends: | The Company does not expect to pay dividends for the foreseeable future. Any decision to pay dividends will be made by the Company’s board of directors on the basis of the Company’s consolidated earnings, financial requirements and other conditions existing at the relevant time. |
